Biocon Biologics, Viatris get EC approval for biosimilar Bevacizumab

Abevmy 100 and 400 mg is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen
Read Article

Biocon Biologics, a subsidiary of Biocon, announced that Abevmy 100 & 400 mg, a biosimilar of Bevacizumab co-developed with Viatris has received marketing authorisation approval from the European Commission following the positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.

Abevmy 100 and 400 mg is approved for the treatment of metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.

The centralised marketing authorisation granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.

AbevmybevacizumabBiocon BiologicsbiosimilarCHMPEuropean Commissionmarketing authorisation
Comments (0)
Add Comment